August 24, 2016 03:38 PM EDTUpdated September 12, 06:08 PM
Bioregnum
R&D
Opinion

Biotech has a bad day af­ter politi­cos pounce on an­oth­er drug pric­ing scan­dal

Call it the Hillary ef­fect. Or Mar­tin Shkre­li on steroids.

The Nas­daq biotech stock in­dex slid 3.5% Wednes­day af­ter­noon af­ter the tsuna­mi of pub­lic …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

Big leas­es, big­ger re­grets: Biotech slump turns swanky of­fices from as­set in­to li­a­bil­i­ty

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times